FIELD: chemistry.SUBSTANCE: claimed invention relates to isoquinolinone derivatives of formula (I) or to its pharmaceutically acceptable salt, where R1 represents (C1-C5)alkyl, possibly substituted with 1, 2 or 3 groups, independently selected from groups -(C1-C6)alkyl, -(C1-C6)alkyloxy, -OH or -(C1-C6)alkyl-hydroxy, and where one independent substituent of R1 radical, representing -(C1-C6)alkyl, can be possibly condensed with other independent substituent of R1 radical, representing -(C1-C6)alkyl, with formation of saturated (C3-C4)cycloalkyl； R2 represents H； R3 represents (CH2)d-Y and R3 is independently possibly substituted with one or two groups -(C1-C6)alkyl, -NH2, -HN(C1-C6)alkyl, -N-di-(C1-C6)alkyl, -(C1-C6)alkyl-NH2, -(C1-C6)alkyl-hydroxy； Y us selected from heterocycloalkyl, S-(O)e-heterocycloalkyl, S-(O)e-(C1-C6)alkyl- heterocycloalkyl, -SO2NH-(C1-C6)alkyl； d equal 0, 1 and 2； e equals o, 1 or 2； R4 and R5 are independently selected from (C1-C6)alkyl and halogeno； R6 represents H； heterocycloalkyl represents C- or N-bound 5-7-membered non-aromatic cyclic ring, which, when it is C-bound, contains one NR7 atom, and when it is N-bound, contains one N-atom, or one N-atom and one NR7 atom, R7 represents H or (C1-C6)alkyl. Invention also relates to application of formula (I) compound in treatment of chronic obstructive pulmonary disease (COPD) and asthma.EFFECT: obtained are novel isoquinoline derivatives, possessing useful biological properties.21 cl, 9 tbl, 67 exНастоящее изобретение относится к производным изохинолинона формулы (I) или к его фармацевтически приемлемой соли, где R1 представляет собой (С1-С5)алкил, который возможно замещен 1, 2 или 3 группами, независимо выбранными из групп -(С1-С6)алкил, -(С1-С6)алкокси, -ОН или -(С1-С6)алкил-гидрокси, и где один независимый заместитель радикала R1, представляющий собой -(С1-С6)алкил, возможно может быть сконденсирован с другим независимым заместителем радикала R1, представляющим собой -(С1-С6)алкил, с обр
